Beschreibung:
<jats:title>ABSTRACT</jats:title><jats:p>The cardiac sodium‐calcium exchanger (NCX) plays an important role in calcium homeostasis. It is the primary mechanism for removing calcium ions that enter myocytes through L‐type calcium channels on a beat‐to‐beat basis. Its direction of transport is determined by the membrane potential and the ionic concentrations of Na<jats:sup>+</jats:sup> and Ca<jats:sup>2+</jats:sup>, with the forward (or Ca<jats:sup>2+</jats:sup>‐efflux) mode of transport being the dominant mode under physiological conditions. In contrast, the Ca<jats:sup>2+</jats:sup>‐influx mode (or reverse mode) of NCX becomes important in certain pathophysiological conditions, such as myocardial ischemia and reperfusion. Recent discovery of compounds that inhibit the Ca<jats:sup>2+</jats:sup>‐influx mode (or reverse mode) of NCX has generated intense research interest in the pharmacology of NCX. Among the newer NCX inhibitors described to date, 2‐[4‐[(2,5‐difluorophenyl)methoxy]‐phenoxy]‐5‐ethoxyaniline (SEA0400) appears particularly promising in attenuating cardiac, renal, and cerebral ischemia/reperfusion injuries in various experimental models. Moreover, the mixed results that have emerged from clinical trials evaluating the efficacy and safety of inhibitors of the sodium‐hydrogen exchanger (an upstream target in relation to the sodium‐calcium exchanger) in myocardial protection stimulated interest in evaluating NCX as an alternative therapeutic target. This article reviews the pharmacological profile of SEA0400, as presented in the published literature, and discusses the therapeutic potential of this compound in attenuating myocardial ischemia/reperfusion injury.</jats:p>